SCHEMBL265156

SCHEMBL265156

CCN(CC)CCNCc1cccc(C(=O)Nc2c(C)csc2C(=O)NN=Cc2ccc(C)cc2)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.42
NPC1 O15118 5/20 0.42
MEN1 O00255 4/20 0.42
KMT2A Q03164 4/20 0.42
ALDH1A1 P00352 4/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
MAPT P10636 6/20 0.38
SMN1; SMN2 Q16637 4/20 0.38
GAA P10253 2/20 0.38
HPGD P15428 1/20 0.38
BCHE P06276 1/20 0.37
TYMS P04818 1/20 0.37
LMNA P02545 2/20 0.37
ESRRG P62508 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP2C9 P11712 2/20 0.36
CYP2C19 P33261 2/20 0.36
CYP3A4 P08684 1/20 0.36
KDM4E B2RXH2 1/20 0.35
PKM P14618 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265155 1.00 RAB9A (0.42) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL266675 0.93 ALDH1A1 (0.39) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL266676 0.93 ALDH1A1 (0.39) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL267512 0.90 RAB9A (0.40) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL267511 0.90 RAB9A (0.40) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL266823 0.88 RAB9A (0.42) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL266601 0.88 SLC34A2 (0.43) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL266822 0.88 RAB9A (0.42) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL266602 0.88 SLC34A2 (0.43) RAB9ANPC1MEN1KMT2AALDH1A1
SCHEMBL265976 0.87 SLC34A2 (0.49) RAB9AKMT2AALDH1A1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 RAB9A 883/4885NPC1 102/4885MEN1 1194/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 RAB9A 1362/4885NPC1 115/4885MEN1 1638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.